Esperion Therapeutis.Inc. buy Maxi_Scalibusa
Start price
21.01.18
/
50%
€68.78
Target price
22.05.18
€208.81
Performance (%)
-49.25%
End price
22.05.18
€34.91
Summary
This prediction ended on 22.05.18 with a price of €34.91. The BUY prediction by Maxi_Scalibusa for Esperion Therapeutis.Inc. performed very badly with a performance of -49.25%. Maxi_Scalibusa has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -6.346% | -6.346% | 32.751% | -52.839% |
| iShares Core DAX® | 2.331% | 5.140% | 25.000% | 65.619% |
| iShares Nasdaq 100 | 2.077% | 2.956% | 8.935% | 111.545% |
| iShares Nikkei 225® | 2.759% | 7.214% | 22.171% | 56.683% |
| iShares S&P 500 | 1.613% | 2.893% | 6.249% | 68.722% |
Comments by Maxi_Scalibusa for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
(Vom Mitglied beendet)